Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models

The Lancet Public Health

Volumn 1, Issue 1, 2016, Pages e8-e17

  Brisson, Marc ^a,b,c   Bénard, Élodie ^a,b   Drolet, Mélanie ^a   Bogaards, Johannes A ^d   Baussano, Iacopo ^e   Vänskä, Simopekka ^g   Jit, Mark ^h,i   Boily, Marie Claude ^b,c   Smith, Megan A ^j   Berkhof, Johannes ^k   Canfell, Karen ^j,l   Chesson, Harrell W ^m   Burger, Emily A ^n,o   Choi, Yoon H ^h   De Blasio, Birgitte Freiesleben ^o,p   De Vlas, Sake J ^q   Guzzetta, Giorgio ^r   Hontelez, Jan A C ^n,q   Horn, Johannes ^s   Jepsen, Martin R ^t   Kim, Jane J ⁿ   Lazzarato, Fulvio ^e,f   Matthijsse, Suzette M ^q   Mikolajczyk, Rafael ^s   Pavelyev, Andrew ^u   Pillsbury, Matthew ^u   Shafer, Leigh Anne ^v   Tully, Stephen P ^e   Turner, Hugo C ^c   Usher, Cara ^w   Walsh, Cathal ^x   more..

^a Université Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f UNIVERSITY OF TURIN   (Italy)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h PUBLIC HEALTH ENGLAND   (United Kingdom)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j CANCER RESEARCH DIVISION   (Australia)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁿ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^o UNIVERSITY OF OSLO   (Norway)

^p NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^q ERASMUS MEDICAL CENTER   (Netherlands)

^r FONDAZIONE BRUNO KESSLER   (Italy)

^s HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^t UNIVERSITY OF COPENHAGEN   (Denmark)

^u MERCK RESEARCH LABORATORIES   (United States)

^v UNIVERSITY OF MANITOBA   (Canada)

^w National Centre for Pharmacoeconomics   (Ireland)

^x UNIVERSITY OF LIMERICK   (Ireland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AGE; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE CLEARANCE; GENDER; HEALTH CARE POLICY; HEALTH IMPACT ASSESSMENT; HERD IMMUNITY; HIGH INCOME COUNTRY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MATHEMATICAL MODEL; META ANALYSIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; RISK BENEFIT ANALYSIS; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; TRANSMISSION DYNAMIC MODEL; VACCINATION; VIRAL CLEARANCE; VIRUS TRANSMISSION; DISEASE ERADICATION; FEMALE; IMMUNOLOGY; MALE; STATISTICAL MODEL; TRANSMISSION;

DISEASE ERADICATION; FEMALE; HUMANS; IMMUNITY, HERD; MALE; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 85013793096     PISSN: None     EISSN: 24682667     Source Type: Journal    
DOI: 10.1016/S2468-2667(16)30001-9     Document Type: Article

References (58)

1. Clifford, GM, Smith, JS, Aguado, T, Franceschi, S, Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89 (2003), 101–105.
2. Munoz, N, Bosch, FX, de Sanjose, S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003), 518–527.
3. De Vuyst, H, Clifford, GM, Nascimento, MC, Madeleine, MM, Franceschi, S, Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124 (2009), 1626–1636.
4. Kreimer, AR, Clifford, GM, Boyle, P, Franceschi, S, Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 (2005), 467–475.
5. Guan, P, Howell-Jones, R, Li, N, et al. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer 131 (2012), 2349–2359.
6. Garland, SM, Steben, M, Sings, HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 199 (2009), 805–814.
7. Paavonen, J, Naud, P, Salmeron, J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009), 301–314.
8. Garland, SM, Hernandez-Avila, M, Wheeler, CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007), 1928–1943.
9. Brotherton, J, Bloem, P, HPV Vaccination: Current Global Status. Curr Obstet Gynecol Rep 4 (2015), 220–233.
10. World Health Organization. Countries with HPV vaccine in the national immunization programme and planned introductions. World Health Organization/IVB Database. http://www.who.int/immunization/diseases/hpv/decision_implementation/en/, January 2014 (accessed Sept 15, 2014).
11. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males. Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60 (2011), 1705–1708.
12. Georgousakis, M, Jayasinghe, S, Brotherton, J, Gilroy, N, Chiu, C, Macartney, K, Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis 12 (2012), 627–634.
13. Switzerland Federal Office of Public Health. Human papillomavirus. http://www.bag.admin.ch/themen/medizin/00682/00684/03853/index.html?lang=en (accessed Dec 18, 2015).
14. Department of Health and Wellness. Prince Edward Island. Immunization schedule. http://www.gov.pe.ca/health/immunizationschedule (accessed Dec 18, 2015).
15. Alberta Health Services. Alberta prevents cancer. http://albertapreventscancer.ca/reduce-your-risk/prevent-hpv-infections/ (accessed Dec 18, 2015).
16. Ministère de la Santé et des Services Sociaux du Québec (MSSS). Vaccin contre les infections par les virus du papillome humain (VPH). http://sante.gouv.qc.ca/conseils-et-prevention/vaccin-contre-les-infections-par-les-virus-du-papillome-humain-vph/ (accessed Dec 18, 2015).
17. Austrian Ministry of Health. HPV vaccination. http://www.bmg.gv.at/home/Timeline/Timeline/?timeline_mode=list&yat-table1-filters-tags=Pr%C3%A4vention (accessed Feb 26, 2016).
18. Markowitz, LE, Dunne, EF, Saraiya, M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rec 63 (2014), 1–30.
19. Comité sur l'immunisation du Québec (CIQ) et Comité scientifique ad hoc VPH. La Vaccination contre les VPH au Québec: Mise à jour des connaissances et propositions du comité d'experts. Direction des risques biologiques et de la santé au travail, Institut national de santé publique Québec (INSPQ), 2012: chapter 2.
20. Canadian Immunization Committee. Recommendations on a human papillomavirus immunization program, 2007, Canadian Immunization Committee, Ontario.
21. JCVI. Human papillomavirus vaccines to protect against cervical cancer, 2008, Joint Committee on Vaccination and Immunisation, London.
22. World Health Organization. Evidence based recommendations on Human Papilloma Virus (HPV) vaccines schedules: Background paper for SAGE discussions. http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf, March 11, 2014 (accessed July 23, 2014).
23. Advisory Committee on Immunization Practices (ACIP). Meeting of the Advisory Committee on Immunization Practices (ACIP) October 29–30, 2014—Summary Report, 2015, Centers for Disease Control and Prevention (CDC), Atlanta.
24. Joura, EA, Giuliano, AR, Iversen, OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372 (2015), 711–723.
25. Brisson, M, Van de Velde, N, Boily, MC, Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 12 (2009), 343–351.
26. Fesenfeld, M, Hutubessy, R, Jit, M, Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine 31 (2013), 3786–3804.
27. Jit, M, Brisson, M, Portnoy, A, Hutubessy, R, Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health 2 (2014), e406–e414.
28. Brisson, M, van de Velde, N, Franco, EL, Drolet, M, Boily, MC, Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 204 (2011), 372–376.
29. Choi, YH, Jit, M, Gay, N, Cox, A, Garnett, GP, Edmunds, WJ, Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 28 (2010), 4091–4102.
30. Bogaards, JA, Kretzschmar, M, Xiridou, M, Meijer, CJ, Berkhof, J, Wallinga, J, Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med, 8, 2011, e1001147.
31. Kim, JJ, Goldie, SJ, Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ, 339, 2009, b3884.
32. Chesson, HW, Ekwueme, DU, Saraiya, M, Dunne, EF, Markowitz, LE, The cost-effectiveness of male HPV vaccination in the United States. Vaccine 29 (2011), 8443–8450.
33. Elbasha, EH, Dasbach, EJ, Impact of vaccinating boys and men against HPV in the United States. Vaccine 28 (2010), 6858–6867.
34. Ben Hadj Yahia, MB, Jouin-Bortolotti, A, Dervaux, B, Extending the human papillomavirus vaccination programme to include males in high-income countries: a systematic review of the cost-effectiveness studiess. Clin Drug Investig 35 (2015), 471–485.
35. Smith, MA, Lew, JB, Walker, RJ, Brotherton, JM, Nickson, C, Canfell, K, The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine, 29, 2011, 9122 9122.
36. Bogaards, JA, Wallinga, J, Brakenhoff, RH, Meijer, CJ, Berkhof, J, Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ, 350, 2015, h2016.
37. Drolet, M, Benard, E, Boily, MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15 (2015), 565–580.
38. Ali, H, Donovan, B, Wand, H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ, 346, 2013, f2032.
39. Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
40. Pitman, R, Fisman, D, Zaric, GS, et al. Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Med Decis Making 32 (2012), 712–721.
41. Shafer, LA, Jeffrey, I, Elias, B, Shearer, B, Canfell, K, Kliewer, E, Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model. Vaccine 31 (2013), 4848–4855.
42. Ryser, MD, McGoff, K, Herzog, DP, Sivakoff, DJ, Myers, ER, Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies. Epidemics 11 (2015), 32–47.
43. Brisson, M, Van de Velde, N, Boily, MC, Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex Transm Infect 87 (2011), 41–43.
44. Weinstein, MC, O'Brien, B, Hornberger, J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 6 (2003), 9–17.
45. Beachler, DC, Jenkins, G, Safaeian, M, Kreimer, AR, Wentzensen, N, Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis 213 (2016), 1444–1454.
46. Smith, MA, Canfell, K, Testing previous model predictions against new data on human papillomavirus vaccination program outcomes. BMC Res Notes, 7, 2014, 109.
47. Elfstrom, KM, Lazzarato, F, Franceschi, S, Dillner, J, Baussano, I, Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. J Infect Dis 213 (2016), 199–205.
48. Brisson, M, Van de Velde, N, Drolet, M, et al. HPV-advise: technical appendices. http://www.marc-brisson.net/HPVadviseCEA.pdf (accessed Aug 2, 2016).
49. Wellings, K, Collumbien, M, Slaymaker, E, et al. Sexual behaviour in context: a global perspective. Lancet 368 (2006), 1706–1728.
50. de Sanjose, S, Diaz, M, Castellsague, X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7 (2007), 453–459.
51. Clifford, GM, Smith, JS, Plummer, M, Munoz, N, Franceschi, S, Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 (2003), 63–73.
52. Bruni, L, Diaz, M, Castellsague, X, Ferrer, E, Bosch, FX, de Sanjose, S, Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202 (2010), 1789–1799.
53. Adler, DH, Kakinami, L, Modisenyane, T, et al. Increased regression and decreased incidence of HPV-related cervical lesions among HIV-infected women on HAART. AIDS 26 (2012), 1645–1652.
54. Baussano, I, Lazzarato, F, Brisson, M, Franceschi, S, Human papillomavirus vaccination at a time of changing sexual behavior. Emerg Infect Dis 22 (2016), 18–23.
55. Greenland, S, Can meta-analysis be salvaged?. Am J Epidemiol 140 (1994), 783–787.
56. Bailar, JC 3rd, The promise and problems of meta-analysis. N Engl J Med 337 (1997), 559–561.
57. Lemieux-Mellouki P, Drolet M, Jit M, Brisson M. Modelling multi-site transmission of HPV and its impact on vaccine effectiveness against HPV. 30th International Papillomavirus Conference; Lisbon, Portugal; Sept 17–21, 2015.
58. Korostil, IA, Regan, DG, The potential impact of HPV-16 reactivation on prevalence in older Australians. BMC Infect Dis, 14, 2014, 312.